The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Seagen; Shattuck Labs; Sutro Biopharma; Tesaro
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Lorena Fariñas-Madrid
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD Oncology
Travel, Accommodations, Expenses - AstraZeneca Spain; GlaxoSmithKline; MSD Oncology
 
Carmen García-Duran
Speakers' Bureau - AstraZeneca Spain; GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
 
Lainie P. Martin
Consulting or Advisory Role - Elucida Oncology; Immunogen; Myriad Genetics; Sutro Biopharma
Research Funding - Agenus (Inst); AstraZeneca (Inst); Immunogen (Inst); Sutro bioPharma (Inst)
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; Arcus Biosciences; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; InxMed; Jazz Pharmaceuticals; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Takeda; Toray Industries; Umoja Biopharma; VBL Therapeutics; Verastem; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Russell J. Schilder
Consulting or Advisory Role - Celsion; Clovis Oncology; Eisai; Incyte; Nextcure; OncXerna Therapeutics
 
Denise Uyar
No Relationships to Disclose
 
John William Moroney
No Relationships to Disclose
 
John Paul Diaz
Speakers' Bureau - AstraZeneca
Research Funding - Merck (Inst)
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Jesus Garcia-Donas
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Meyers-Squibb/Statistical Horizons; Merck; Pfizer; Roche
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb
 
Michael Palumbo
Employment - Sutro Biopharma
Stock and Other Ownership Interests - Genentech; Sutro Biopharma
 
Hatem Dokainish
Employment - Genentech; Sutro Biopharma
Stock and Other Ownership Interests - Genentech; Sutro Biopharma
 
Lin Liu
Employment - Sutro Biopharma
Stock and Other Ownership Interests - Sutro Biopharma
 
Craig Jerome Berman
Employment - Sutro Biopharma
Stock and Other Ownership Interests - Sutro Biopharma
 
R. Wendel Naumann
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Suibb; Clovis Oncology; Eisai; Genelux; GlaxoSmithKline/Tesaro; GOG Partners; Laekna Therapeutics; Merck Sharp & Dohme; OncoMed; Seagen; Sutro Biopharma
Speakers' Bureau - Seagen
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Gynecologic Oncology Group (Inst); Mersana (Inst); OncoMed (Inst); Sutro Biopharma (Inst)